A Open-label, Randomized, Crossover Study to Assess PK of Pregabalin
A Open-label, Randomized, Crossover Study to Assess PK of Pregabalin
The purpose of this trial to compare the pharmacokinetic characteristics of
 YHD1119(Pregabalin 300mg) and Lyrica capsule(Pregabalin 150mg). YHD1119 is controlled release
 formulation which is made by Yuhan Corporation. Primary endpoints are Cmax,ss and AUCtau and
 secondary endpoints are AUClast,ss, AUCinf,ss, Tmax,ss and t1/2.
Inclusion Criteria:

 -  19~50 years old, healthy male volunteers

 -  >55Kg(Body weight) and 18.5<BMI<28

 Exclusion Criteria:

 -  AST or ALT > 3 * Upper normal range (Lab)

 -  Total bilirubin > 2.0 mg/dl

 -  Systolic BP >140 OR <90, Diastolic BP >100 OR <60